![]() Norman Schwartz, Bio-Rad’s Chief Executive Officer, commented: “Having exceeded all of the long-term financial targets we outlined in 2017, we are now excited to share the details of our growth strategy and how we are poised to enhance our financial profile even further. We define core revenue as currency neutral non-GAAP revenue and excludes COVID-related sales. For 2025, the Company expects to enhance its financial profile even further, targeting about 9% core revenue CAGR from 2021 to 2025, and 28% adjusted EBITDA margin in 2025. During the event, members of Bio-Rad’s executive leadership team will provide an in-depth overview of the Company’s growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life Science Research and Clinical Diagnostics.ĭuring its investor day in 2017, Bio-Rad stated a target revenue growth range of 3-5%, and an adjusted EBITDA margin target of 20%+ in 2020, both of which the Company exceeded. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. Paladin has over $950 million dollars of committed capital across multiple funds and 37 portfolio companies.Bio-Rad Laboratories, Inc. Headquartered in Washington, D.C., Paladin Capital Group is a leading multi-stage private equity firm providing capital for growing companies whose principal business centers on products and services that address homeland security issues and needs. “This elegant solution expands the current state-of-the-art methods of quantitative PCR” “We are impressed with QuantaLife’s digital PCR technology and believe it will complement Bio-Rad’s existing amplification business” says Norman Schwartz, Bio-Rad president and CEO. The result helped turn QuantaLife into the promising business it is today. “As a member of the Board, Paul really rolled up his sleeves and helped me through all the various challenges facing a first time CEO at a young startup,” Colston said. Paul Conley, a Principal at the firm with deep experience in helping startups navigate the challenges of commercializing a technology and managing growth, immediately stepped in to help. When Paladin began working with QuantaLife, the startup was basically a few brilliant guys from Lawrence Livermore National Laboratory with a good idea. We’re grateful for the support and commitment of Paladin who took a risk on us very early and stuck by us through thick and thin.” “We look forward to seeing our technology fulfill its potential to save and improve lives in the future as part of the Bio-Rad family. “This is a great outcome for QuantaLife’s employees and investors,” said Bill Colston, CEO of QuantaLife. The technology not only helps in the fight against all manner of cancer and disease but also the drug-resistant viral infections, like MRSA, that are increasingly found inside hospitals. Digital PCR offers researchers a new tool for the detection of mutations, including rare sequences in tumors, precise measurement of copy number variation and absolute quantification of gene expression. QuantaLife developed a digital PCR system called Droplet Digital™ (ddPCR) that identifies cancer and other specified molecules with unmatched precision and sensitivity. ![]() Steed, Founder and Managing Partner of Paladin Capital Group. “We’re proud of the guidance and support we were able to provide QuantaLife and are absolutely thrilled that this company and its promise for helping to effectively treat diseases like cancer and drug-resistant viruses will continue to prosper with Bio-Rad Laboratories,” said Michael R. Paladin helped nurture QuantaLife from a tiny startup with a great idea to a dynamic company that is helping to accelerate the search for causes, cures and diagnostics for many important diseases, including cancer, HIV and genetic birth defects. Washington DC – QuantaLife, one of the nation’s most promising life sciences companies, was purchased this week by Bio-Rad Laboratories for $162 million – marking another successful exit for Paladin Capital Group.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |